Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Glucotrack (GCTK) Change in Accured Expenses (2016 - 2020)

Glucotrack's Change in Accured Expenses history spans 7 years, with the latest figure at -$143000.0 for Q4 2020.

  • For the quarter ending Q4 2020, Change in Accured Expenses rose 15.52% year-over-year to -$143000.0, compared with a TTM value of -$236000.0 through Dec 2020, up 18.9%, and an annual FY2025 reading of $17000.0, up 104.04% over the prior year.
  • Change in Accured Expenses for Q4 2020 was -$143000.0 at Glucotrack, down from $55000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $937276.0 in Q1 2017, with the low at -$766248.0 in Q2 2017.
  • Average Change in Accured Expenses over 5 years is $34653.1, with a median of $29536.0 recorded in 2018.
  • Biggest YoY gain for Change in Accured Expenses was 328.19% in 2016; the steepest drop was 2653.73% in 2016.
  • Tracing GCTK's Change in Accured Expenses over 5 years: stood at $133830.0 in 2016, then skyrocketed by 99.94% to $267582.0 in 2017, then crashed by 74.5% to $68237.0 in 2018, then plummeted by 348.06% to -$169268.0 in 2019, then increased by 15.52% to -$143000.0 in 2020.
  • Per Business Quant, the three most recent readings for GCTK's Change in Accured Expenses are -$143000.0 (Q4 2020), $55000.0 (Q3 2020), and -$99000.0 (Q2 2020).